LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a r ...

Voyager Therapeutics (VYGR) shares rallied 17.5% in the last trading session to close at $7.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.5% loss over the past four weeks. The sudden surge in the company's stock price can be attributed to the positive momentum built around its pipeline. Voyager is evaluating its anti-tau antibody, VY7523 (formerly VY-TAU01), in an early-stage study for Alzheimer's dis ...

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences: The Wells Fargo 2024 Healthcare Conference, in Boston, including a fireside chat at 1:30 p.m. ET on September 5, 2024 The Baird 2024 Global Healthcare Conference, in New York City, including a fireside chat at 1:25 p.m. ET on September 11, 2024 Webcasts ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer Alfred Sandrock - Chief Executive Officer Toby Ferguson - Chief Medical Officer Nathan Jorgensen - Chief Financial Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird & Co. Divya Rao - TD Cowen Ry Forseth - Guggenheim Securities Mehdi Goudarzi - Truist Securities Sumant Kulkarni - Canacc ...

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be ar ...

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be a ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 52.63%. A quarter ago, it was expected that this gene therapy company would post a loss of $0.44 per share when it actually produced a loss of $0.20, delivering a surprise of 54.55%. Over the last four quarters, the ...

Table of Contents Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Delaware 46-3003182 (S ...

EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results – Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease – – Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate – – Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chi ...

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the ...